Argent Capital Management LLC Buys Shares of 185,725 MiMedx Group, Inc (NASDAQ:MDXG)

Argent Capital Management LLC acquired a new stake in MiMedx Group, Inc (NASDAQ:MDXG) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 185,725 shares of the medical equipment provider’s stock, valued at approximately $2,780,000. Argent Capital Management LLC owned approximately 0.17% of MiMedx Group at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MDXG. Acrospire Investment Management LLC lifted its stake in shares of MiMedx Group by 678.9% in the 2nd quarter. Acrospire Investment Management LLC now owns 6,769 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 5,900 shares in the last quarter. Quantbot Technologies LP acquired a new position in MiMedx Group during the 2nd quarter worth approximately $109,000. Victory Capital Management Inc. lifted its position in MiMedx Group by 15.4% during the 1st quarter. Victory Capital Management Inc. now owns 14,616 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 1,952 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in MiMedx Group during the 2nd quarter worth approximately $157,000. Finally, Great Lakes Advisors LLC acquired a new position in MiMedx Group during the 2nd quarter worth approximately $163,000. 60.37% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Argent Capital Management LLC Buys Shares of 185,725 MiMedx Group, Inc (NASDAQ:MDXG)” was posted by BBNS and is owned by of BBNS. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://baseballnewssource.com/markets/argent-capital-management-llc-buys-shares-of-185725-mimedx-group-inc-mdxg/1702270.html.

Shares of MiMedx Group, Inc (NASDAQ:MDXG) traded down 1.16% on Wednesday, reaching $13.66. The company’s stock had a trading volume of 1,120,425 shares. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 71.89 and a beta of 0.91. MiMedx Group, Inc has a 52 week low of $7.64 and a 52 week high of $17.47. The stock has a 50-day moving average of $13.56 and a 200 day moving average of $13.90.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.07 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.07. The business had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $74.22 million. MiMedx Group had a net margin of 7.48% and a return on equity of 15.95%. The business’s quarterly revenue was up 33.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.05 earnings per share. On average, analysts expect that MiMedx Group, Inc will post $0.31 EPS for the current year.

MiMedx Group announced that its Board of Directors has approved a share buyback plan on Wednesday, July 26th that permits the company to buyback $14.00 million in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 0.9% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Several research firms have issued reports on MDXG. Lake Street Capital lifted their price objective on MiMedx Group from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, July 28th. BidaskClub downgraded MiMedx Group from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Piper Jaffray Companies reiterated a “buy” rating and issued a $18.00 price target on shares of MiMedx Group in a report on Sunday, August 20th. Needham & Company LLC reiterated a “buy” rating and issued a $20.00 price target (up from $15.00) on shares of MiMedx Group in a report on Monday, June 26th. Finally, Zacks Investment Research downgraded MiMedx Group from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $14.83.

About MiMedx Group

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.